Idyllic Updates

Bristol-Myers Squibb's ORENCIA Receives FDA Approval for Active Psoriatic Arthritis

Administrator

ORENCIA is now approved for the treatment of three autoimmune diseases:

  • Adult Rheumatoid Arthritis (RA)
  • Juvenile Idiopathic Arthritis (JIA)
  • Adult Psoriatic Arthritis (PsA) — NEW

Psoriatic arthritis (PsA) is a chronic, inflammatory disease that can affect both the skin and musculoskeletal system. Approximately 30% of individuals diagnosed with Psoriasis have PsA.

Symptoms of PsA include joint pain, stiffness, and reduced range of motion. PsA most commonly affects the distal joints (those closest to the nail) of the fingers or toes, as well as the wrists, knees, ankles, and lower back. Joint symptoms typically include swelling, redness, and warmth of a few or many joints, often in an asymmetric fashion. Individuals between the ages of 30 to 50 are usually affected, though onset can begin as early as childhood, with men and women equally at risk.

Individuals diagnosed with PsA will now have another treatment option that their physician may prescribe.